TY - JOUR
T1 - Developing HME-Based Drug Products Using Emerging Science: a Fast-Track Roadmap from Concept to Clinical Batch
AU - Matic, Josip
AU - Paudel, Amrit
AU - Bauer, Hannes
AU - Garcia, Raymar Andreina Lara
AU - Biedrzycka, Kinga
AU - Khinast, Johannes G.
PY - 2020/6/22
Y1 - 2020/6/22
N2 - This paper presents a rational workflow for developing enabling formulations, such as amorphous solid dispersions, via hot-melt extrusion in less than a year. First, our approach to an integrated product and process development framework is described, including state-of-the-art theoretical concepts, modeling, and experimental characterization described in the literature and developed by us. Next, lab-scale extruder setups are designed (processing conditions and screw design) based on a rational, model-based framework that takes into account the thermal load required, the mixing capabilities, and the thermo-mechanical degradation. The predicted optimal process setup can be validated quickly in the pilot plant. Lastly, a transfer of the process to any GMP-certified manufacturing site can be performed in silico for any extruder based on our validated computational framework. In summary, the proposed workflow massively reduces the risk in product and process development and shortens the drug-to-market time for enabling formulations.
AB - This paper presents a rational workflow for developing enabling formulations, such as amorphous solid dispersions, via hot-melt extrusion in less than a year. First, our approach to an integrated product and process development framework is described, including state-of-the-art theoretical concepts, modeling, and experimental characterization described in the literature and developed by us. Next, lab-scale extruder setups are designed (processing conditions and screw design) based on a rational, model-based framework that takes into account the thermal load required, the mixing capabilities, and the thermo-mechanical degradation. The predicted optimal process setup can be validated quickly in the pilot plant. Lastly, a transfer of the process to any GMP-certified manufacturing site can be performed in silico for any extruder based on our validated computational framework. In summary, the proposed workflow massively reduces the risk in product and process development and shortens the drug-to-market time for enabling formulations.
KW - rational formulation development
KW - hot melt extrusion
KW - amorphous solid dispersions
KW - process and product modeling
UR - http://www.scopus.com/inward/record.url?scp=85086745078&partnerID=8YFLogxK
U2 - 10.1208/s12249-020-01713-0
DO - 10.1208/s12249-020-01713-0
M3 - Review article
SN - 1530-9932
VL - 21
JO - AAPS PharmSciTech
JF - AAPS PharmSciTech
IS - 5
M1 - 176
ER -